Higher sensitivity to patupilone versus paclitaxel chemotherapy in primary uterine serous papillary carcinoma cell lines with high versus low HER-2/neu expression in vitro

Gynecologic Oncology

Volumn 119, Issue 1, 2010, Pages 140-145

  Paik, Daniel ^a   Cocco, Emiliano ^a   Bellone, Stefania ^a   Casagrande, Francesca ^a   Bellone, Marta ^a   Siegel, Eric E ^b   Richter, Christine E ^a   Schwartz, Peter E ^a   Rutherford, Thomas J ^a   Santin, Alessandro D ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

Endometrial neoplasms; HER 2 neu; Paclitaxel; Patupilone; Uterine serous tumors

Indexed keywords

BETA TUBULIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPOTHILONE B; GLYCOPROTEIN P; PACLITAXEL; ANTINEOPLASTIC AGENT; EPOTHILONE DERIVATIVE; MULTIDRUG RESISTANCE PROTEIN; TUBULIN;

ADULT; AGED; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER RESISTANCE; CELL PROLIFERATION; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG SENSITIVITY; FEMALE; GROWTH RATE; HUMAN; HUMAN CELL; IN VITRO STUDY; NITROBLUE TETRAZOLIUM TEST; PAPILLARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; UTERINE SEROUS PAPILLARY CARCINOMA; UTERUS CARCINOMA; BIOSYNTHESIS; CARCINOMA, PAPILLARY; CYSTADENOCARCINOMA, SEROUS; DOSE RESPONSE; DRUG SCREENING; ENZYMOLOGY; METABOLISM; TUMOR CELL LINE; UTERINE NEOPLASMS;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CARCINOMA, PAPILLARY; CELL LINE, TUMOR; CYSTADENOCARCINOMA, SEROUS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; EPOTHILONES; FEMALE; HUMANS; P-GLYCOPROTEIN; PACLITAXEL; RECEPTOR, ERBB-2; TUBULIN; UTERINE NEOPLASMS;

EID: 77956651097     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2010.06.024     Document Type: Article

References (38)

1. M. Thun, J. Xu, Y. Hao, E. Ward, R. Siegel, and A. Jemal Cancer statistics, 2009 CA Cancer J Clin 59 2009 225
2. J.V. Bokhman Two pathogenetic types of endometrial carcinoma Gynecol Oncol 15 1983 10
3. M. Hendrickson, J. Ross, P. Eifel, A. Martinez, and R. Kempson Uterine papillary serous carcinoma: a highly malignant form of endometrial adenocarcinoma Am J Surg Pathol 6 1982 93 108
4. C. Levenback, T.W. Burke, and E. Silva Uterine papillary serous carcinoma (USPC) treated with cisplatin, doxorubicin, and cyclophosphamide (PAC) Gynecol Oncol 46 1992 317 321
5. L. Nicklin, and L.J. Copeland Endometrial papillary serous carcinoma: pattern of spread and treatment Clin Obstet Gynecol 39 1996 686 695
6. P.E. Schwartz The management of serous papillary uterine cancer Curr Opin Oncol 18 5 2006 494 499
7. J.J. Lee, and S.M. Swain The epothilones: translating from the laboratory to the clinic Clin Cancer Res 14 6 2008 1618 1624
8. G. Höfle, N. Bedorf, H. Steinmetz, D. Schumberg, K. Gerth, and H. Reichenbach Epothilones A and B-novel 16-membered macrolides with cytotoxic activity: isolation, crystal structure, and conformation in solution Angew Chem Int Ed Engl 35 1996 1567 1569
9. F.Y. Lee, R. Borzilleri, C.R. Fairchild, S.H. Kim, B.H. Long, and C. Reventos-Suarez BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy Clin Cancer Res 7 2001 1429 1437
10. R.J. Kowalski, P. Giannakakou, and E. Hamel Activities of the microtubule-stabilizing agents epothilones A and B with purified tubulin and in cells resistant to paclitaxel J Biol Chem 272 1997 2534 2541
11. P. Giannakakou, R. Gassio, E. Nogales, K.H. Downing, D. Zaharevitz, and B. Bollbuck A common pharmacophore for epothilone and taxanes: molecular basis for drug resistance conferred by tubulin mutations in human cancer cells Proc Natl Acad Sci 97 1999 2094 2909
12. S. Forli, F. Manetti, K. Altmann, and M. Botta Evaluation of novel epothilone analogues by means of a common pharmacophore and a QSAR pseudoreceptor model for taxanes and epothilone ChemMedChem 5 2010 35 40
13. A.D. Santin, S. Bellone, S. Van Stedum, W. Bushen, L.E. De Las Casas, and S. Korourian Determination of HER-2/neu status in uterine serous papillary carcinoma: comparative analysis of immunohistochemistry and fluorescence in situ hybridization Gynecol Oncol 98 2005 24 30
14. A.D. Santin, S. Bellone, S. Van Stedum, W. Bushen, M. Palmieri, and E.R. Siegel Amplification of c-erbB2 oncogene: a major prognostic indicator in uterine serous papillary carcinoma Cancer 104 7 2005 1391 1397
15. A.D. Santin, S. Bellone, E.R. Siegel, M. Palmieri, M. Thomas, and M.J. Cannon Racial differences in overexpression of epidermal growth factor type II receptor (HER2/neu): a major prognostic indicator in uterine serous papillary cancer Am J Obstet Gynecol 192 2005 813 818
16. T.P. Diaz-Montes, H. Ji, A.E. Smith Sehdev, M.L. Zahurak, R.J. Kurman, and D.K. Armstrong Clinical significance of HER-2/neu overexpression in uterine serous carcinoma Gynecol Oncol 100 2006 139 144
17. T.A. Grushko, V.L. Filiaci, A.J. Mundt, K. Ridderstrale, O.I. Olopade, and G.F. Fleming An exploratory analysis of HER-2 amplification and overexpression in advanced endometrial carcinoma: a Gynecologic Oncology Group study. Gynecologic Oncology Group Gynecol Oncol 108 1 2008 3 9
18. C. Wright, B. Angus, S. Nicholson, J.R. Sainsbury, J. Cairns, and W.J. Gullick Expression of c-erbB-2 oncoprotein: a prognostic indicator in human breast cancer Cancer Res 49 1989 2087 2090
19. A. Berchuck, A. Kamel, R. Whitaker, B. Kerns, G. Olt, and R. Kinney Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer Cancer Res 50 1990 4087 4091
20. D.J. Hetzel, T.O. Wilson, G.L. Keeney, P.C. Roche, S.S. Cha, and K.C. Podratz HER-2/neu expression: a major prognostic factor in endometrial cancer Gynecol Oncol 47 1992 179 185
21. K. El-Sahwi, S. Bellone, E. Cocco, M. Cargnelutti, F. Casagrande, and M. Bellone In vitro activity of pertuzumab in combination with trastuzumab in uterine serous papillary adenocarcinoma Br J Cancer 102 1 2010 134 143
22. P. Giannakakou, D.L. Sackett, Y.K. Kang, Z. Zhan, J.T. Buters, and T. Fojo Paclitaxel-resistant human ovarian cancer cells have mutant β-tubulins that exhibit impaired paclitaxel-driven polymerization J Biol Chem 272 1997 17118 17125
23. M. Kavallaris, D. Kuo, C. Burkhart, D.L. Regl, M.D. Norris, and M. Haber Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific β-tubulin isotypes J Clin Invest 100 1997 1282 1293
24. S. Mozzetti, R. Iantomasi, I. De Maria, S. Prislei, M. Mariani, and A. Camperchioli Molecular mechanisms of patupilone resistance Cancer Res 68 24 2008 10197 10204
25. J.T. Thigpen, H.J. Buchsbaum, C. Mangan, and J.A. Blessing Phase II trial of adriamycin in the treatment of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study Cancer Treat Rep 63 1979 21 27
26. J.T. Thigpen, J.A. Blessing, H. Homesley, W.T. Creasman, and G. Sutton Phase II trial of cisplatin as first-line chemotherapy in patients with advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study Gynecol Oncol 33 1989 68 70
27. H.G. Ball, J.A. Blessing, S.S. Lentz, and D.G. Mutch A phase II trial of paclitaxel in patients with advanced or recurrent adenocarcinoma of the endometrium: a Gynecologic Oncology Group study Gynecol Oncol 62 1996 278 281
28. G.F. Fleming, V.L. Brunetto, D. Cella, K.Y. Look, G.C. Reid, and A.R. Munkarah Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group study J Clin Oncol 22 2004 2159 2166 (Pubitemid 41095150)
29. Y. Yarden, and M.X. Sliwkowski Untangling the erbB signaling network Nat Rev Mol Cell Biol 2 2001 127 137
30. M.D. Pegram, R.S. Finn, K. Arzoo, M. Beryt, R.J. Pietras, and D.J. Slamon The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells Oncogene 15 1997 537 547
31. T. Chen, A. Molina, S. Moore, S. Goel, K. Desai, and A. Hamilton Epothilone B analog (BMS-247550) at the recommended phase II dose (RPTD) in patients with gyneologic and breast cancers J Clin Oncol 22(Suppl) 2004 155s (Abstr 2115)
32. K. De Geest, J.A. Blessing, R.T. Morris, S.D. Yamada, B.J. Monk, and S.L. Zweizig Phase II clinical trial of ixabepilone in patients with recurrent or persistent platinum- and taxane-resistant ovarian or primary peritoneal cancer: a Gynecologic Oncology Group Study J Clin Oncol 28 2009 149 153
33. D.S. Dizon, J.A. Blessing, D.S. McMeekin, S.K. Sharma, P. Disilvestro, and R.D. Alvarez Phase II trial of ixabepilone as second-line treatment in advanced endometrial cancer: Gynecologic Oncology Group Trial 129-P J Clin Oncol 27 19 2009 3104 3108
34. M. Gottesman Mechanisms of cancer drug resistance Annu Rev Med 53 2002 613 627
35. M.M. Baekelandt, R. Holm, J.M. Nesland, C.G. Trope, and G.B. Kristensen P-glycoprotein expression is a marker for chemotherapy resistance and prognosis in advanced ovarian cancer Anticancer Res 20 2000 1061 1067
36. R.T. Penson, E. Oliva, S.J. Skates, T. Glyptis, A.F. Fuller, and A. Goodman Expression of multidrug resistance-1 protein inversely correlates with paclitaxel response and survival in ovarian cancer patients: a study in serial samples Gynecol Oncol 93 2004 98 106
37. G. Ferrandina, G. Zannoni, E. Martinelli, A. Paglia, V. Gallotta, and S. Mozzetti Class III β-tubulin overexpression is a marker of poor clinical outcome in advanced ovarian cancer patients Clin Cancer Res 12 9 2006
38. T. Umezu, K. Shibata, H. Kajiyama, M. Terauchi, K. Ino, and A. Nawa Taxol resistance among the different histological subtypes of ovarian cancer may be associated with the expression of class III β-tubulin Int J Gynecol Pathol 27 2008 207 212